Tak­ing on gam­ma delta T cells, blue­bird pays $16M for TC Bio­Phar­m's tu­mor in­vad­ing tech plat­form

Gene ther­a­py pi­o­neer blue­bird bio is team­ing up with Scot­land’s TC Bio­Pharm to get its hands on an ex­per­i­men­tal pro­gram in­volv­ing an emerg­ing im­munother­a­py plat­form …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER